Skip to main content
SpringerLink
Log in

The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer

  • Chapter
  • First Online:
Protein-Protein Interactions

Part of the book series: Topics in Medicinal Chemistry ((TMC,volume 8))

Abstract

Apoptosis is a genetically regulated process of cell death that is critical for cellular homeostasis. Dysregulation of apoptosis can lead to the absence of normal cell death and contribute to cancer development and progression. The Inhibitor of Apoptosis (IAP) proteins contain up to three baculovirus IAP repeat (BIR) domains that interact with members of the caspase family of proteases, thereby blocking apoptosis. Select BIR domains of IAP proteins contain a defined protein-protein interaction region with the N-terminal amino acid residues of the natural IAP antagonist protein, SMAC. Antagonizing this interaction formed the basis of all drug discovery efforts and has yielded promising drug candidates. One member of the IAP family, XIAP, can inhibit caspases 3 and 7 through its BIR2 domain and caspase-9 with its BIR3 domain. The c-IAPs play a key role in the regulation of the NF-κB pathways, which is manipulated by the IAP antagonists to yield single agent activity. SMAC mimicking IAP antagonists can be monovalent, representing an equivalent of four amino acid residues from the processed SMAC, or bivalent – having two units connected through a chemical linker. In addition, antagonists specific for a particular IAP protein or a group of IAPs have been reported. So far, six molecules have entered clinical trials with early results showing no dose limiting toxicities and suggesting that IAP proteins can be targeted by small molecules.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Reed JC (2002) Apoptosis-based therapies. Nat Rev Drug Discov 1(2):111–121

    Article  CAS  Google Scholar 

  2. Salvesen GS, Duckett CS (2002) IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol 3(6):401–410

    Article  CAS  Google Scholar 

  3. Varfolomeev E, Vucic D (2011) Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets. Future Oncol 7(5):633–648

    Article  CAS  Google Scholar 

  4. Miller LK (1999) An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol 9(8):323–328

    Article  CAS  Google Scholar 

  5. Vaux DL, Silke J (2005) IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 6(4):287–297

    Article  CAS  Google Scholar 

  6. Vucic D, Dixit VM, Wertz IE (2011) Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 12(7):439–452

    Article  CAS  Google Scholar 

  7. Blankenship JW, Varfolomeev E, Goncharov T et al (2009) Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). Biochem J 417(1):149–160

    Article  CAS  Google Scholar 

  8. Gyrd-Hansen M, Darding M, Miasari M et al (2008) IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol 10(11):1309–1317

    Article  CAS  Google Scholar 

  9. Hofmann K, Bucher P, Tschopp J (1997) The CARD domain: a new apoptotic signalling motif. Trends Biochem Sci 22(5):155–156

    Article  CAS  Google Scholar 

  10. Varfolomeev E, Vucic D (2008) (Un)expected roles of c-IAPs in apoptotic and NF-κB signaling pathways. Cell Cycle 7(11):1511–1521

    Article  CAS  Google Scholar 

  11. Hunter AM, LaCasse EC, Korneluk RG (2007) The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12(9):1543–1568

    Article  CAS  Google Scholar 

  12. Salvesen GS, Abrams JM (2004) Caspase activation – stepping on the gas or releasing the brakes? Lessons from humans and flies. Oncogene 23(16):2774–2784

    Article  CAS  Google Scholar 

  13. Kaufmann SH, Vaux DL (2003) Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 22(47):7414–7430

    Article  CAS  Google Scholar 

  14. Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281(5381):1305–1308

    Article  CAS  Google Scholar 

  15. Eckelman BP, Salvesen GS, Scott FL (2006) Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 7(10):988–994

    Article  CAS  Google Scholar 

  16. Chai J, Shiozaki E, Srinivasula SM et al (2001) Structural basis of caspase-7 inhibition by XIAP. Cell 104(5):769–780

    Article  CAS  Google Scholar 

  17. Huang Y, Park YC, Rich RL et al (2001) Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 104(5):781–790

    CAS  Google Scholar 

  18. Riedl SJ, Renatus M, Schwarzenbacher R et al (2001) Structural basis for the inhibition of caspase-3 by XIAP. Cell 104(5):791–800

    Article  CAS  Google Scholar 

  19. Scott FL, Denault JB, Riedl SJ et al (2005) XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J 24(3):645–655

    Article  CAS  Google Scholar 

  20. Suzuki Y, Nakabayashi Y, Nakata K et al (2001) X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes. J Biol Chem 276(29):27058–27063

    Article  CAS  Google Scholar 

  21. Shiozaki EN, Chai J, Rigotti DJ et al (2003) Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 11(2):519–527

    Article  CAS  Google Scholar 

  22. Srinivasula SM, Hegde R, Saleh A et al (2001) A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410(6824):112–116

    Article  CAS  Google Scholar 

  23. Du C, Fang M, Li Y et al (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102(1):33–42

    Article  CAS  Google Scholar 

  24. Verhagen AM, Ekert PG, Pakusch M et al (2000) Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102(1):43–53

    Article  CAS  Google Scholar 

  25. Burri L, Strahm Y, Hawkins CJ et al (2005) Mature DIABLO/Smac is produced by the IMP protease complex on the mitochondrial inner membrane. Mol Biol Cell 16(6):2926–2933

    Article  CAS  Google Scholar 

  26. Liu Z, Sun C, Olejniczak ET et al (2000) Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 408(6815):1004–1008

    Article  CAS  Google Scholar 

  27. Wu G, Chai J, Suber TL et al (2000) Structural basis of IAP recognition by Smac/DIABLO. Nature 408(6815):1008–1012

    Article  CAS  Google Scholar 

  28. Vucic D, Deshayes K, Ackerly H et al (2002) SMAC negatively regulates the anti-apoptotic activity of Melanoma Inhibitor of Apoptosis (ML-IAP). J Biol Chem 277(14):12275–12279

    Article  CAS  Google Scholar 

  29. Vucic D, Fairbrother WJ (2007) The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 13(20):5995–6000

    Article  CAS  Google Scholar 

  30. Vucic D (2008) Targeting IAP (inhibitor of apoptosis) proteins for therapeutic intervention in tumors. Curr Cancer Drug Targets 8(2):110–117

    Article  CAS  Google Scholar 

  31. Verhagen AM, Kratina TK, Hawkins CJ et al (2007) Identification of mammalian mitochondrial proteins that interact with IAPs via N-terminal IAP binding motifs. Cell Death Differ 14(2):348–357

    Article  CAS  Google Scholar 

  32. Liston P, Fong WG, Kelly NL et al (2001) Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nat Cell Biol 3(2):128–133

    Article  CAS  Google Scholar 

  33. Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296(5573):1634–1635

    Article  CAS  Google Scholar 

  34. Varfolomeev E, Goncharov T, Fedorova AV et al (2008) c-IAP1 and c-IAP2 are critical mediators of Tumor Necrosis Factor alpha (TNFα)-induced NF-κB activation. J Biol Chem 283(36):24295–24299

    Article  CAS  Google Scholar 

  35. Bertrand MJ, Milutinovic S, Dickson KM et al (2008) cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 30(6):689–700

    Article  CAS  Google Scholar 

  36. Dynek JN, Goncharov T, Dueber EC et al (2010) c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J 29(24):4198–4209

    Article  CAS  Google Scholar 

  37. Varfolomeev E, Blankenship JW, Wayson SM et al (2007) IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 131(4):669–681

    Article  CAS  Google Scholar 

  38. Mahoney DJ, Cheung HH, Mrad RL et al (2008) Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 105(33):11778–11783

    Article  CAS  Google Scholar 

  39. Haas TL, Emmerich CH, Gerlach B et al (2009) Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 36(5):831–844

    Article  CAS  Google Scholar 

  40. Vince JE, Wong WW, Khan N et al (2007) IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131(4):682–693

    Article  CAS  Google Scholar 

  41. Schile AJ, Garcia-Fernandez M, Steller H (2008) Regulation of apoptosis by XIAP ubiquitin-ligase activity. Genes Dev 22(16):2256–2266

    Article  CAS  Google Scholar 

  42. Hu S, Yang X (2003) Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. J Biol Chem 278(12):10055–10060

    Article  CAS  Google Scholar 

  43. MacFarlane M, Merrison W, Bratton SB et al (2002) Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 277(39):36611–36616

    Article  CAS  Google Scholar 

  44. Wright CW, Duckett CS (2008) New insights into the function of IAP proteins: modulation of the MYC/MAX/MAD network. Dev Cell 14(1):3–4

    Article  CAS  Google Scholar 

  45. Fulda S, Vucic D (2012) Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 11:109–124

    Google Scholar 

  46. Vucic D, Stennicke HR, Pisabarro MT et al (2000) ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 10(21):1359–1366

    Article  CAS  Google Scholar 

  47. Gong J, Chen N, Zhou Q et al (2005) Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas. J Clin Pathol 58(10):1081–1085

    Article  CAS  Google Scholar 

  48. Gazzaniga P, Gradilone A, Giuliani L et al (2003) Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 14(1):85–90

    Article  CAS  Google Scholar 

  49. Kempkensteffen C, Hinz S, Christoph F et al (2007) Expression of the apoptosis inhibitor livin in renal cell carcinomas: correlations with pathology and outcome. Tumour Biol 28(3):132–138

    Article  CAS  Google Scholar 

  50. Crnkovic-Mertens I, Wagener N, Semzow J et al (2007) Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis. Cell Mol Life Sci 64(9):1137–1144

    Article  CAS  Google Scholar 

  51. Dynek JN, Chan SM, Liu J et al (2008) Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res 68(9):3124–3132

    Article  CAS  Google Scholar 

  52. Hu Y, Cherton-Horvat G, Dragowska V et al (2003) Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 9(7):2826–2836

    CAS  Google Scholar 

  53. Sasaki H, Sheng Y, Kotsuji F et al (2000) Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 60(20):5659–5666

    CAS  Google Scholar 

  54. Bilim V, Kasahara T, Hara N et al (2003) Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer 103(1):29–37

    Article  CAS  Google Scholar 

  55. McManus DC, Lefebvre CA, Cherton-Horvat G et al (2004) Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 23(49):8105–8117

    Article  CAS  Google Scholar 

  56. Ryan BM, O'Donovan N, Duffy MJ (2009) Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 35(7):553–562

    Article  CAS  Google Scholar 

  57. LaCasse EC, Mahoney DJ, Cheung HH et al (2008) IAP-targeted therapies for cancer. Oncogene 27(48):6252–6275

    Article  CAS  Google Scholar 

  58. Zender L, Spector MS, Xue W et al (2006) Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125(7):1253–1267

    Article  CAS  Google Scholar 

  59. Akagi T, Motegi M, Tamura A et al (1999) A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18(42):5785–5794

    Article  CAS  Google Scholar 

  60. Dierlamm J, Baens M, Stefanova-Ouzounova M et al (2000) Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using API2 and MLT specific probes. Blood 96(6):2215–2218

    CAS  Google Scholar 

  61. Dierlamm J, Baens M, Wlodarska I et al (1999) The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6ssociated with mucosa- associated lymphoid tissue lymphomas. Blood 93(11):3601–3609

    CAS  Google Scholar 

  62. Morgan JA, Yin Y, Borowsky AD et al (1999) Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res 59(24):6205–6213

    CAS  Google Scholar 

  63. Imoto I, Yang ZQ, Pimkhaokham A et al (2001) Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res 61(18):6629–6634

    CAS  Google Scholar 

  64. Imoto I, Tsuda H, Hirasawa A et al (2002) Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res 62(17):4860–4866

    CAS  Google Scholar 

  65. Isaacson PG (2005) Update on MALT lymphomas. Best Pract Res Clin Haematol 18(1):57–68

    Article  CAS  Google Scholar 

  66. Fulda S, Wick W, Weller M et al (2002) Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8(8):808–815

    CAS  Google Scholar 

  67. Arnt CR, Chiorean MV, Heldebrant MP et al (2002) Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 277(46):44236–44243

    Article  CAS  Google Scholar 

  68. Franklin MC, Kadkhodayan S, Ackerly H et al (2003) Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). Biochemistry 42(27):8223–8231

    Article  CAS  Google Scholar 

  69. Oost TK, Sun C, Armstrong RC et al (2004) Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 47(18):4417–4426

    Article  CAS  Google Scholar 

  70. Gaither A, Porter D, Yao Y et al (2007) A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 67(24):11493–11498

    Article  CAS  Google Scholar 

  71. Zobel K, Wang L, Varfolomeev E et al (2006) Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol 1(8):525–533

    Article  CAS  Google Scholar 

  72. Sun H, Nikolovska-Coleska Z, Lu J et al (2006) Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. J Med Chem 49(26):7916–7920

    Article  CAS  Google Scholar 

  73. Sun H, Nikolovska-Coleska Z, Yang CY et al (2004) Structure-based design of potent, conformationally constrained Smac mimetics. J Am Chem Soc 126(51):16686–16687

    Article  CAS  Google Scholar 

  74. Sun H, Nikolovska-Coleska Z, Yang CY et al (2008) Design of small-molecule peptidic and nonpeptidic Smac mimetics. Acc Chem Res 41(10):1264–1277

    Article  CAS  Google Scholar 

  75. Li L, Thomas RM, Suzuki H et al (2004) A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science 305(5689):1471–1474

    Article  CAS  Google Scholar 

  76. Probst BL, Liu L, Ramesh V, Li L, Sun H, Minna JD, Wang L (2010) Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner. Cell Death Differ 17(10):9

    Article  Google Scholar 

  77. Varfolomeev E, Alicke B, Elliott JM et al (2009) X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem 284(50):34553–34560

    Article  CAS  Google Scholar 

  78. Sun H, Nikolovska-Coleska Z, Lu J et al (2007) Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc 129(49):15279–15294

    Article  CAS  Google Scholar 

  79. Petersen SL, Wang L, Yalcin-Chin A et al (2007) Autocrine TNFalpha signaling renders human cancer cells susceptible to smac-mimetic-induced apoptosis. Cancer Cell 12(5):445–456

    Article  CAS  Google Scholar 

  80. Wang L, Du F, Wang X (2008) TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133(4):693–703

    Article  CAS  Google Scholar 

  81. Feltham R, Bettjeman B, Budhidarmo R et al (2011) Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. J Biol Chem 286(19):17015–17028

    Article  CAS  Google Scholar 

  82. Mace PD, Linke K, Feltham R et al (2008) Structures of the cIAP2 RING domain reveal conformational changes associated with ubiquitin-conjugating enzyme (E2) recruitment. J Biol Chem 283(46):31633–31640

    Article  CAS  Google Scholar 

  83. Wertz IE, Kusam S, Lam C et al (2011) Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471(7336):110–114

    Article  CAS  Google Scholar 

  84. Ndubaku C, Varfolomeev E, Wang L et al (2009) Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem Biol 4(7):557–566

    Article  CAS  Google Scholar 

  85. Genentech (2007) A study of the safety and pharmacokinetics of GDC-0152, administered intravenously to patients with locally advanced or metastatic malignancies. http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00977067.

  86. Sikic BI, Eckhardt SG, Gallant G, et al (2011) Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: results of a phase I study. In: 2011 annual ASCO meeting, Chicago, IL

    Google Scholar 

  87. Infante JR, Dees EC, Burris HA III, et al (2010) A phase I study of LCL-161, an oral IAP inhibitor, in patients with advanced cancer. In: The annual meeting of the American Association for Cancer Research, Washington, DC

    Google Scholar 

  88. Amaravadi RK, Schilder RJ, Dy GK, et al (2011) Phase 1 study of the smac mimetic TL32711 in adult subjects with advanced solid tumors & lymphoma to evaluate safety, pharmacokinetics, pharmacodynamics and anti-tumor activity. In: 2011 annual AACR conference, Orlando, FL

    Google Scholar 

  89. Genentech (2010) I. A study evaluating the safety, tolerability and pharmacokinetics of GDC-0917 administered to patients with refractory solid tumors or lymphoma. http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01226277.

  90. Cai Q, Sun H, Peng Y et al (2011) A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 54(8):2714–2726

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Early Discovery Biochemistry, Genentech Inc., South San Francisco, CA, 94080, USA

    Kurt Deshayes & Domagoj Vucic

  2. Department of Structural Biology, Genentech Inc., South San Francisco, CA, 94080, USA

    Jeremy Murray

Authors
  1. Kurt Deshayes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeremy Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Domagoj Vucic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kurt Deshayes .

Editor information

Editors and Affiliations

  1. , Global Pharmaceutical R & D, Abbott Laboratories, Dept R4N6 / Bldg AP10-3, Abbott Park Rd 100, Abbott Park, 60064, Illinois, USA

    Michael D. Wendt

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Deshayes, K., Murray, J., Vucic, D. (2012). The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer. In: Wendt, M. (eds) Protein-Protein Interactions. Topics in Medicinal Chemistry, vol 8. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-28965-1_3

Download citation

Publish with us

Policies and ethics

Search

Navigation